RBR-7bxhrtRecruitingPhase 3
Chloroquine chemoprophylaxis in a high-risk population for the prevention of SARS-CoV-2 infections severity of infection. Randomized clinical trial ofphase III
Instituto René Rachou/FIOCRUZ Minas0 sitesStarted: July 14, 2020Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 3
- Status
- Recruiting
- Sponsor
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Intervention
Eligibility Criteria
- Ages
- 18Y to 65Y (—)
Inclusion Criteria
- •Health professionals attending patients with suspected SARS-CoV-2 infection.
- •sign the informed consent.
- •Willing to adhere to the study protocol.
Exclusion Criteria
- •Known allergy to the study drug (aminoquinolines).
- •flu-related symptoms at the time of inclusion.
- •Previous or current SARS-Cov2 infection confirmed.
- •Known pregnancy (no pregnancy test required).
- •History of retinopathy.
- •ECG changes with enlargement of the QT interval.
- •Weight less than 40 kg
- •Participant with any immunosuppressive condition or hematological disease.
- •Treatment with drugs that can prolong the QT interval or increase the number of adverse events in the last month before randomization for more than 7 days, including: azithromycin, chlorpromazine, cisapride, clarithromycin, domperidone, droperidol, erythromycin, halofantrine, haloperidol, lumefantrine, mefloquine, methadone, pentamidine, procainamide, cimetidine, quinidine, quinine, sotalol, sparfloxacin, thioridazine, amiodarone, Dapsone
Investigators
Similar Trials
Active, not recruiting
Phase 1
Chloroquine/ hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting; a randomised, placebo-controlled prophylaxis study (COPCOV)Profliaxis of SARS-CoV-2 infectionMedDRA version: 23.0Level: LLTClassification code 10053983Term: Corona virus infectionSystem Organ Class: 100000004862EUCTR2020-001441-39-ITIVERSITY OF OXFORD40,000
Active, not recruiting
Phase 1
Chloroquine/ hydroxychloroquine prevention of COVID-19 (COPCOV)EUCTR2020-001441-39-GBniversity of Oxford10,000
Completed
Phase 3
Hydroxychloroquine Chemoprophylaxis in Healthcare Personnel in Contact With COVID-19 Patients (PHYDRA Trial)COVID-19Severe Acute Respiratory SyndromeNCT04318015National Institute of Respiratory Diseases, Mexico289
Recruiting
Phase 3
Hydroxychloroquine for prevention of COVID-19Coronavirus diseasePACTR202009786901147Dr. William Schilling1,600
Completed
Phase 2
Prevention With Chloroquine in Health Personnel Exposed to Infection With Coronavirus Disease 2019 (COVID-19) (TS-COVID)Covid19NCT04627467Fundacion Clinica Valle del Lili3,217